loading net worth // from filings
robert davis net worth // filing-anchored
Robert Davis Net Worth (2026)
Robert Davis is Chairman & CEO of Merck (MRK). Most of a public-company CEO’s on-paper wealth is their stake in that company — anchored here on the number you can verify.
WHAT WE ESTIMATE
varies
Past cash compensation, sold shares, real estate, and other public holdings — estimable from records, but not exact.
WHAT CAN’T BE KNOWN
private
Private company stakes, trusts, cash, debts, and undisclosed assets. Anyone publishing these as a single number is guessing.
At a glance
| Company | Merck (MRK) |
| Title | Chairman & CEO |
| Verified stake | $57M |
| Shares owned | 450,351 |
| Latest total pay | $21M breakdown → |
| Age | ~60 |
HOW THIS IS CALCULATED
We take the shares Robert Davis reports owning in their most recent SEC Form 4 and multiply by the latest share price. That gives a stake value you can check against the filing itself. Everything beyond that stake — real estate, private holdings, cash, past compensation — is estimated or simply not public, and we say so rather than roll it into one number.
BIOGRAPHY
Robert Davis built his career at the intersection of finance and medicine. He studied finance at Miami University in Ohio and collected both an MBA and a law degree from Northwestern, then spent about fourteen years at Eli Lilly before moving to the medical-products maker Baxter International, where he served as chief financial officer and ran a major business unit.
He joined Merck as chief financial officer in 2014, gradually taking on strategy and other functions, and became chief executive in 2021, succeeding Kenneth Frazier. His tenure has centered on Merck’s cancer-drug franchise and the spinoff of its women’s-health business into Organon.
Davis is a hired executive. His Merck stake came from executive compensation, which is what this page measures.
Born 1966 · Miami University (BS); Kellogg (MBA); Northwestern Pritzker School of Law (JD)
CAREER
NOTABLE
- Reached the top job at Merck through finance, joining as chief financial officer before becoming chief executive.
- Chairs the board of the drug-industry group PhRMA and sits on the board of Duke Energy.
COMPENSATION HISTORY · from SEC proxy statements
| Fiscal year | Total pay |
|---|---|
| 2025 | $21M |
The richest CEOs
Ranked by filing-verified stake
The stake value is filing-derived and verifiable; any broader “net worth” is an estimate. Share counts are the latest reported on SEC filings and change as the executive trades; the price is the last close, so the stake value moves with the market. This is not an official or complete accounting of anyone’s wealth. Educational only — not investment advice.
